Literature DB >> 17942914

Transcriptional regulation of human protease-activated receptor 1: a role for the early growth response-1 protein in prostate cancer.

Zaidoun Salah1, Myriam Maoz, Gallina Pizov, Rachel Bar-Shavit.   

Abstract

Transcriptional regulation plays a central role in the molecular pathways underlying preferential cancer growth and metastasis. In the present study, we investigated the regulation of human protease-activated receptor 1 (hPar1) gene overexpression in the malignant androgen hormone-resistant phase. We found increased hPar1 RNA chain elongation and no change in message stability in cells with high levels of PAR1 expression, indicating that increased transcription is largely responsible for the overexpression of hPar1 in prostate tumor progression. Enforced expression of early growth response-1 (Egr-1) plasmid markedly enhanced luciferase activity driven by the hPar1 promoter. The neuroendocrine peptide bombesin significantly induced hPar1 expression and increased the ability of the cells to invade Matrigel, an effect abolished by expression of hPar1 small interfering RNA, showing the importance of hPAR1 in invasion. Bombesin also markedly enhanced Egr-1 binding to the hPar1 promoter in vivo and in vitro. These data suggest that bombesin enhances Egr-1 expression leading to increased hPar1 transcription, thereby increasing PAR1 expression and function. Immunohistostaining of prostate tissue biopsy specimens revealed a direct correlation between the degree of prostate cancer malignancy, PAR1 expression, and EGR-1 expression. Altogether, we show that transcriptional regulation of hPar1 in the aggressive hormone-resistant prostate cancer stage is controlled in part by the transcription factor Egr-1 and may play a central role in invasiveness, an important indicator of malignancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942914     DOI: 10.1158/0008-5472.CAN-07-1886

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Causes of genome instability: the effect of low dose chemical exposures in modern society.

Authors:  Sabine A S Langie; Gudrun Koppen; Daniel Desaulniers; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Amaya Azqueta; William H Bisson; Dustin G Brown; Gunnar Brunborg; Amelia K Charles; Tao Chen; Annamaria Colacci; Firouz Darroudi; Stefano Forte; Laetitia Gonzalez; Roslida A Hamid; Lisbeth E Knudsen; Luc Leyns; Adela Lopez de Cerain Salsamendi; Lorenzo Memeo; Chiara Mondello; Carmel Mothersill; Ann-Karin Olsen; Sofia Pavanello; Jayadev Raju; Emilio Rojas; Rabindra Roy; Elizabeth P Ryan; Patricia Ostrosky-Wegman; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Frederik J Van Schooten; Mahara Valverde; Jordan Woodrick; Luoping Zhang; Nik van Larebeke; Micheline Kirsch-Volders; Andrew R Collins
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

2.  A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma.

Authors:  Kathryn T Bieging; Kamonwan Fish; Subbarao Bondada; Richard Longnecker
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

3.  Early growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization.

Authors:  Anna C Jones; Kristina A Trujillo; Genevieve K Phillips; Trisha M Fleet; Jaclyn K Murton; Virginia Severns; Satyan K Shah; Michael S Davis; Anthony Y Smith; Jeffrey K Griffith; Edgar G Fischer; Marco Bisoffi
Journal:  Prostate       Date:  2011-11-29       Impact factor: 4.104

4.  EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF.

Authors:  Gabi Tarcic; Roi Avraham; Gur Pines; Ido Amit; Tal Shay; Yiling Lu; Yaara Zwang; Menachem Katz; Nir Ben-Chetrit; Jasmine Jacob-Hirsch; Laura Virgilio; Gideon Rechavi; George Mavrothalassitis; Gordon B Mills; Eytan Domany; Yosef Yarden
Journal:  FASEB J       Date:  2011-12-23       Impact factor: 5.191

5.  Oral thrombostatin FM19 inhibits prostate cancer.

Authors:  Marvin T Nieman; Gretchen LaRusch; Chao Fang; Yihua Zhou; Alvin H Schmaier
Journal:  Thromb Haemost       Date:  2010-09-30       Impact factor: 5.249

6.  Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappaB synergy.

Authors:  Jiajia Ma; Zijia Ren; Yang Ma; Lu Xu; Ying Zhao; Chaogu Zheng; Yinghui Fang; Ting Xue; Baolin Sun; Weihua Xiao
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

Review 7.  Is EGR1 a potential target for prostate cancer therapy?

Authors:  Delphine Gitenay; Véronique T Baron
Journal:  Future Oncol       Date:  2009-09       Impact factor: 3.404

8.  Par genes: molecular probes to pathological assessment in breast cancer progression.

Authors:  Beatrice Uziely; Hagit Turm; Myriam Maoz; Irit Cohen; Bella Maly; Rachel Bar-Shavit
Journal:  Patholog Res Int       Date:  2011-01-24

9.  Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways.

Authors:  Roy Blum; Rashmi Gupta; Patricia E Burger; Christopher S Ontiveros; Sarah N Salm; Xiaozhong Xiong; Alexander Kamb; Holger Wesche; Lisa Marshall; Gene Cutler; Xiangyun Wang; Jiri Zavadil; David Moscatelli; E Lynette Wilson
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

10.  Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.

Authors:  Martin B Oleksiewicz; Jennifer Southgate; Lars Iversen; Frederikke L Egerod
Journal:  PPAR Res       Date:  2009-01-28       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.